


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents Washington, D.C. 20231 On

12 May 23, 2002  
By *Tonya Weston*

OTPE



JUN 05 2002 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT & TRADEMARK OFFICE  
re application of:

Jay A. Berzofsky et al.

Examiner: J. Stucker

RECEIVED

JUN 12 2002

Application No.: 09/508,552

Art Unit: 1648

TECH CENTER 1600/2900

Filed: June 12, 2000

AMENDMENT AND RESPONSE TO  
RESTRICTION REQUIREMENT

For: MUCOSAL CYTOTOXIC T  
LYMPHOCYTE RESPONSES

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This is in response to the Restriction Requirement dated January 8, 2002.

Please consider the following amendments and remarks prior to substantive examination of the present application.

IN THE SPECIFICATION:

Please amend the specification as set forth in detail herein below. An Appendix showing all changes to the specification is attached to this amendment as required by 37 CFR § 1.121(b).

Kindly replace the paragraph at page 5, line 34 to page 6, line 4, with the following paragraph:

B1  
Also provided within the invention are immunogenic compositions for inducing a protective mucosal CTL response in a subject which are adapted for intrarectal administration. The compositions comprise a purified soluble antigen formulated for intrarectal delivery to the rectum, colon, sigmoid colon, or distal colon. They may be formulated as a rectal enema, foam, suppository, or topical gel and generally comprise a base, carrier, or absorption-promoting agent adapted for intrarectal delivery.